What's hot
View all perspectives
Jiha Lee JihaRheum
9 months 4 weeks ago
🌟 Join us for the Aging Strong session at #ACR24!
We are thrilled to have Dr Cynthia Boyd, division director of Geriatrics at Hopkins, visit us to discuss how to manage multicomplexity in older rheumatic patients.
#GeriRheum @RheumNow
@cynthiaboyd16 @UnaMakris https://t.co/QZpOmdgzOR
Antoni Chan MD (Prof) synovialjoints
9 months 4 weeks ago
A 6-year study of the link between alcohol consumption and spinal radiographic progression in axial spondyloarthritis (axSpA). Results indicate that alcohol may worsen spinal damage, particularly in males and those with radiographic axSpA. Future research should explore… https://t.co/IIvTyq7kBe
sheila RHEUMarampa
9 months 4 weeks ago
Using #MachineLearning for predicting flares in axSpA @DiegoBenavent et al, data from METEOR-SpA registry showed the ff predictors of flares thru the reduced logistic regression model:
🔅lower ASDAS
🔅enthesitis
🔅prior flares
🔅longer treatment duration
@RheumNow #ACR24 abs559 https://t.co/wyIo9gnKVJ
Mrinalini Dey DrMiniDey
9 months 4 weeks ago
📈 Data from @UIowa_Rheum on how rurality impacts delay to diagnosis in #GCA
📍 0747
👉🏼 People living in more rural areas have an increased time to diagnosis & treatment- further prospective studies needed to delineate effects of rurality further
@RheumNow #ACR24
@LemonReneeNi https://t.co/3YMcI9ha3T
Richard Conway RichardPAConway
9 months 4 weeks ago
Harkins @DrTrishHarkins et al. People with PMR exhibit an accelerated physical aging phenotype at baseline. High rates of frailty (41%), pre-frailty (28%), cognitive impairment (74%!), sarcopenia (23%), osteoporosis (21%) @RheumNow #ACR24 Abstr#0740 https://t.co/4ZT8VtGi1W https://t.co/xBQ5CLlb5A
Akhil Sood MD AkhilSoodMD
9 months 4 weeks ago
Does apremilast have cardiometabolic benefits?
Abstract 0598: In PsA patients, 1-year treatment with apremilast associated w/ ↓ body fat mass, including android fat, and was linked w/ improved disease activity (DAS28-CRP). #ACR24 @RheumNow https://t.co/11n4gQN7Xo
sheila RHEUMarampa
9 months 4 weeks ago
Characteristics of difficult-to-treat AS accdg to a retrospective study by @DaoudAnsaam @mmagrey1 et al
⬆️ BMI
+ comorbidities: HTN, CKD, depression
+ EAMs: IBD, Pso, iridocyclitis
+ HLA-B27
Interesting real world data.
@RheumNow #ACR24 abs573 https://t.co/GlE4tFpsSz
Dr. John Cush RheumNow
9 months 4 weeks ago
FDA has given FDA Breakthrough Therapy designation to Nipocalimab for treatment of adults w/ moderate-to-severe Sjögren’s disease. NIPO is an Ab to neonatal Fc receptor (FcRn), & was tested and shown effective in Sjog in the Phase 2 DAHLIAS study - a plenary presentation at… https://t.co/aQDp7iPKXD https://t.co/hJ8fe6JwxC
Caoilfhionn Connolly CaoilfhionnMD
9 months 4 weeks ago
#0588
🔬 Sex Differences in PsA
➡️n=1405, pooled RCT data
♀️49%: Milder PsO (PASI 7.8 v 11.5), higher BMI, longer PsA duration,⬆️ fatigue/pain vs ♂️
♀️worse QoL/functional impairment
♂️More dactylitis (45% v 37%)
🩺 Sex-specific factors matter in PsA
#ACR24 @RheumNow
Richard Conway RichardPAConway
9 months 4 weeks ago
Puechal et al. Serial ANCA testing may predict relapse in a large group of AAV patients but is NOT useful for individual patients. @RheumNow #ACR24 Abstr#0721 https://t.co/ClvTk2Tlar https://t.co/k4vc7l9jzK
Caoilfhionn Connolly CaoilfhionnMD
9 months 4 weeks ago
#0589
🔬Time to Response in PsA Domains: Secukinumab
➡️Post-hoc analyses, n=1366
🔑Median time (wks) to MCID 👇
🔴Systemic inflammation <2
🔴MSK: ~4 wks (enthesitis~12)
🔴Fatigue~7–8
🔴PASI75~8–12; nails ~24
🩺 Rapid MSK & QoL benefits precede skin/nail
#ACR24 @RheumNow https://t.co/WfqkryA1CC
sheila RHEUMarampa
9 months 4 weeks ago
Data from the study by Dr. Aguilar et al showed that high dose NSAID use was not assoc'd with incident HTN in their cohort of early axSpA patients.
Shows important role of NSAIDs in #axSpA but still should be used judiciously
@RheumNow #ACR24 abs540
@rheum_cat @rheumarhyme https://t.co/LK5yFZynu4
Antoni Chan MD (Prof) synovialjoints
9 months 4 weeks ago
Switching vs cycling - which is better? In PsA & axSpA, a real-world analysis shows that switching to IL-17Ai after TNFi discontinuation may lead to similar or better outcomes compared to cycling to another TNFi. Data from the CorEvitas PsA/SpA Registry. Abstr#0585.… https://t.co/AJP4NBjmzr
Richard Conway RichardPAConway
9 months 4 weeks ago
De Lorenzis et al. MMF in LcSSc. Target Trial Emulation. 1435 patients. Incidence vasodilator treatment escalation over 41 months, 1/100py in MMF vs 7.3/100py in controls. @RheumNow #ACR24 Abstr#0688 https://t.co/D3qTUHyIIc https://t.co/6azvaS0ElL
Richard Conway RichardPAConway
9 months 4 weeks ago
Galloway et al report OCP/HRT use in RA is not associated with VTE in UK population based study. Increased risk by having RA, HR 1.52. Risk OCP HR 1.43, HRT HR 2.32 - neither statistical significant but very wide CI's! Hmm... @RheumNow #ACR24 Abstr#0134 https://t.co/CZNoRfYWe8 https://t.co/uC6jA9lcX9
Poster Hall